化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变患者的疗效观察

doi:10.3760/cma.j.issn.1007-1245.2024.07.016

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (7): 1136-1141.DOI: 10.3760/cma.j.issn.1007-1245.2024.07.016

化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变患者的疗效观察

王满华¹ 张韬² 张永刚³

¹安康市中医医院眼科，安康　725000；²西安交通大学第一附属医院眼科，西安　710061；³榆阳中医康复医院中医科，榆林　719000

收稿日期:2024-01-03 出版日期:2024-03-01 发布日期:2024-05-04
通讯作者: 张永刚，Email：yonggang198342@163.com
基金资助:
陕西省自然科学基础研究计划（2020JM7021）

Curative effect of Huayu Fuming Decoction combined with calcium oxybenzenesulfonate capsules for patients with early diabetic retinopathy

Wang Manhua¹, Zhang Tao², Zhang Yonggang³

¹Department of Ophthalmology, Ankang Hospital of Traditional Chinese Medicine, Ankang 725000, China; ²Department of Ophthalmology, First Hospital, Xi'an Jiaotong Univeristy, Xi'an 710061, China; ³Department of Traditional Chinese Medicine, Yuyang Chinese Medicine Rehabilitation Hospital, Yulin 719000, China

Received:2024-01-03 Online:2024-03-01 Published:2024-05-04
Contact: Zhang Yonggang, Email: yonggang198342@163.com
Supported by:
Basic Research Plan of Natural Science in Shaanxi (2020JM7021)

摘要/Abstract

摘要：

目的　探讨化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变（DR）患者的疗效。方法　前瞻性研究，按随机数字表法将安康市中医医院2020年5月至2023年5月收治的104例DR患者分为对照组（52例）与治疗组（52例）。对照组男29例，女23例，年龄（45.91±1.83）岁，给予羟苯磺酸钙胶囊治疗，0.5 g/次，3 次/d。治疗组男27例，女25例，年龄（45.82±1.79）岁，在对照组的基础上联合化瘀复明汤治疗，200 ml为1剂，每日1剂。两组均治疗１个月。比较两组治疗前、后中医证候及中文版低视力者生活质量量表（CLVQOL）评分、黄斑厚度、出血斑面积、各血糖指标、血清血管内皮生长因子（VEGF）、血小板衍生生长因子（PDGF）及白细胞介素-1（IL-1）水平变化，统计两组疗效与不良反应发生情况。统计学方法采用t检验、χ²检验。结果　治疗组总有效率高于对照组［96.15%（50/52）比82.69%（43/52）］，差异有统计学意义（χ²=4.98，P=0.026）。治疗后，治疗组中医证候积分低于对照组［（7.28±1.36）分比（11.71±1.50）分］，CLVQOL评分高于对照组［（113.25±10.48）分比（89.76±8.17）分］，差异均有统计学意义（t=15.78、12.75，均P<0.05）。治疗后，治疗组黄斑厚度、出血斑面积均低于对照组［（306.42±11.09）μm比（355.37±13.17）μm、（1.04±0.26）mm²比（1.85±0.37）mm²］，差异均有统计学意义（t=20.50、12.92，均P<0.001）。治疗后，治疗组空腹血糖（FBG）、2 hFBG、糖化血红蛋白（HbAlc）水平均低于对照组［（6.30±1.18）mmol/L比（7.35±1.24）mmol/L、（15.40±4.25）mmol/L比（17.35±4.32）mmol/L、（3.76±0.95）μmol/L比（5.41±1.12）μmol/L］，差异均有统计学意义（t=4.42、2.32、8.10，均P<0.05）。治疗后，治疗组VEGF、PDGF、IL-1水平均低于对照组［（88.75±14.03）μg/L比（136.22±17.41）μg/L、（4.43±0.97）μg/L比（6.12±1.08）μg/L、（21.06±4.05）ng/L比（25.42±4.57）ng/L］，差异均有统计学意义（t=15.31、8.40、3.97，均P<0.05）。治疗组不良反应发生率低于对照组［3.85％（2/52）比15.38％（8/52）］，差异有统计学意义（χ²=3.98，P<0.05）。结论　化瘀复明汤联合羟苯磺酸钙治疗DR患者疗效理想，能够改善中医证候、提升生活质量、减轻黄斑损伤和血糖水平，降低血清VEGF、PDGF及IL-1水平，不良反应发生率低，具备较好的安全性，值得推广。

关键词:

糖尿病视网膜病变, 血管内皮生长因子, 化瘀复明汤, 羟苯磺酸钙, 血小板衍生生长因子

Abstract:

Objective　To explore the curative effect of Huayu Fuming Decoction combined with calcium oxybenzenesulfonate capsules for patients with diabetic retinopathy (DR). Methods　One hundred and four patients with DR treated at Ankang Hospital of Traditional Chinese Medicine from May 2020 to May 2023 were selected for the randomized control trial, and were divided into a control group (52 cases) and a treatment group (52 cases) by the random number table method. There 29 males and 23 females in the control group; they were (45.91±1.83) years old. There were 27 males and 25 females in the treatment group; they were (45.82±1.79) years old. The control group were treated with calcium oxybenzenesulfonate capsules,0.5 g each time, 3 times a day, and the treatment group with calcium oxybenzenesulfonate capsules and Huayu Fuming decoction, 200 ml was 1 dose, 1 dose per day, for 1 month. The Chinese medicine syndromes, scores of Chinese version of Quality of Life Scale for Low Vision (CLVQOL), macular thicknesses, blood spot areas, levels of blood glucose indicators, and serum levels of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and interleukin-1 (IL-1) were compared between the two groups before and after treatment. The efficacies the and adverse reactions in both groups were statistically analyzed. t and χ² tests were used for the statistical comparison. Results　The total effective rate of the treatment group was higher than that of the control group [96.15% (50/52) vs. (82.69% (43/52), with a statistical difference (χ²=4.98, P=0.026). After the treatment, the scores of traditional Chinese medicine syndrome and CLVQOL in the treatment group were better than those in the control group [(7.28±1.36) vs. (11.71±1.50) and (113.25±10.48) vs. (89.76±8.17)], with statistical differences (t=15.78 and 12.75; both P<0.05). After the treatment, the macular thickness and the area of blood stains decreased in both groups. After the treatment, the macular thickness and blood spot area in the treatment group were lower than those in the control group [(306.42±11.09) μm vs. (355.37±13.17) μm and (1.04±0.26) mm² vs. (1.85±0.37) mm²], with statistical differences (t=20.50 and 12.92; both P<0.001). After the treatment, the levels of fasting blood glucose (FBG), 2 h fasting blood glucose (2 hFBG), and glycosylated hemoglobin (HbAlc) in the treatment group were lower than those in the control group [(6.30±1.18) mmol/L vs. (7.35±1.24) mmol/L, (15.40±4.25) mmol/L vs. (17.35±4.32) mmol/L, and (3.76±0.95) μmol/L vs. (5.41±1.12) μmol/L], with statistical differences (t=4.42, 2.32, and 8.10; all P<0.05). After the treatment, the levels of VEGF, PDGF, and IL-1 in the treatment group were lower than those in the control group [(88.75±14.03) μg/L vs. (136.22±17.41) μg/L, (4.43±0.97) μg/L vs. (6.12±1.08) μg/L, (21.06±4.05) ng/L vs. (25.42±4.57) ng/L], with statistical differences (t=15.31, 8.40, and 3.97; all P<0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group [3.85% (2/52) vs. 15.38% (8/52)], with a statistical difference (χ²=3.98; P<0.05). Conclusion　Huayu Fusing Decoction combined with calcium oxybenzenesulfonate capsules for patients with DR has ideal effect, and can improve their traditional Chinese medicine syndromes and quality of life, and reduce macular injury, blood glucose level, and serum levels of VEGF, PDGF, and IL-1, with a low incidence of adverse reactions and good safety, so it is worthy of promotion.

Key words:

Diabetic retinopathy, Vascular endothelial growth factor, Huayu Fuming Decoction, Calcium oxybenzenesulfonate, Platelet-derived growth factor

王满华张韬张永刚.

化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变患者的疗效观察 [J]. 国际医药卫生导报, 2024, 30(7): 1136-1141.

Wang Manhua, Zhang Tao, Zhang Yonggang.

Curative effect of Huayu Fuming Decoction combined with calcium oxybenzenesulfonate capsules for patients with early diabetic retinopathy [J]. International Medicine and Health Guidance News, 2024, 30(7): 1136-1141.

参考文献

[1] 潘锋. 糖尿病防治的重点在预防和治疗并发症[J]. 中国医药导报,2022,19(35):1-3.
[2] Sadikan MZ, Abdul Nasir NA. Diabetic retinopathy: emerging concepts of current and potential therapy[J]. Naunyn Schmiedebergs Arch Pharmacol,2023,396(12):3395-3406.DOI: 10.1007/s00210-023-02599-y.
[3] 贾琼,罗向霞,苏梅贵,等. 糖尿病视网膜病变早期优化代谢治疗研究进展[J]. 中华眼底病杂志,2021,37(1):68-72. DOI:10.3760/cma.j.cn511434-20200304-00096.
[4] 赵芳,裴超,蔡志鹏,等.糖尿病视网膜病变患者发病危险因素:基于SS-OCTA检测指标的分析[J].眼科新进展,2021,41(7):643-646.DOI:10.13389/j.cnki.rao.2021.0132.
[5] 唐玉洁,胡庆,唐勇,等. 羟苯磺酸钙胶囊联合贝那普利片治疗早期糖尿病肾病患者的临床研究[J]. 中国临床药理学杂志,2022,38(19):2259-2262. DOI:10.13699/j.cnki.1001-6821.2022.19.003.
[6] 邸莎,王天铬,李敏. 中医药治疗糖尿病视网膜病变进展[J]. 辽宁中医杂志,2022,49(1):208-213. DOI:10.13192/j.issn.1000-1719.2022.01.057.
[7] 马学毅.糖尿病防治指南[M].北京:人民卫生出版社,2003:46.
[8] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:312-316.
[9] 金培新,张宏信,宋颖,等. 益气固肾明目方联合雷珠单抗玻璃体腔注射治疗糖尿病黄斑水肿疗效观察[J]. 四川中医,2022,40(3):188-191.
[10] Tan TE, Wong TY. Diabetic retinopathy: looking forward to 2030[J]. Front Endocrinol (Lausanne),2023,13:1077669.DOI: 10.3389/fendo.2022.1077669.
[11] 尹玉如,赵博军. 糖尿病视网膜病变早期诊断技术及其应用[J]. 国际眼科杂志,2022,22(3):438-442. DOI:10.3980/j.issn.1672-5123.2022.3.18.
[12] 雷雯,季艳丹,赵美云,等. 丹心降糖通脉胶囊联合羟苯磺酸钙胶囊治疗糖尿病肾病早期的临床效果[J]. 世界中医药,2021,16(13):2010-2014. DOI:10.3969/j.issn.1673-7202. 2021.13.017.
[13] 彭清华. 糖尿病视网膜病变中西医结合研究现状[J]. 中国中西医结合杂志,2021,41(6):660-662. DOI:10.7661/j.cjim.20210510.077.
[14] 许琳,祝莹,吕波,等. 叔丁基对苯二酚对糖尿病视网膜病变大鼠视网膜新生血管生成及HIF-1α/VEGF通路蛋白的影响[J]. 临床和实验医学杂志,2021,20(12):1241-1245. DOI:10.3969/j.issn.1671-4695.2021.12.003.
[15] 刘博研,赵锦. PDGF、FGF-21、APN在2型糖尿病足患者中的表达及意义[J]. 中国实验诊断学,2023,27(6):683-686. DOI:10.3969/j.issn.1007-4287.2023.06.014.
[16] 柳洁平,孔玉红,王玲. 双丹明目胶囊联合羟苯磺酸钙治疗糖尿病视网膜病变的疗效及对血清VEGF、血小板源性生长因子和白细胞介素1水平的影响[J]. 中国医院用药评价与分析,2019,19(11):1332-1334,1338. DOI:10.14009/j.issn.1672-2124.2019.11.015.
[17] 皮雯敏,韩娜娜,袁枝花,等. 基于"干法+湿法实验"和"配位化学"探讨石膏解热配伍规律及物质基础[J]. 中草药,2022,53(5):1471-1482. DOI:10.7501/j.issn.0253-2670. 2022.05.023.
[18] 张也,孙晓祝,于淼,等. 反相离子对-高效液相色谱法同时测定葛根芩连汤中13种有效成分及其在配伍机制研究中的应用[J]. 中草药,2021,52(16):4852-4859. DOI:10.7501/j.issn.0253-2670.2021.16.010.
[19] 高泽正,杨映映,顾成娟,等. 仝小林运用黄芪、熟地黄、黄精气血精阴并补经验[J]. 吉林中医药,2021,41(2):164-166. DOI:10.13463/j.cnki.jlzyy.2021.02.008.
[20] 于涵,余海源,牟爱敏. 丹参对糖尿病肾病保护机制的研究进展[J]. 世界中医药,2021,16(7):1161-1165. DOI:10.3969/j.issn.1673-7202.2021.07.027.
[21] 范顺明,杨勇勋,张春玲,等. 知母-黄柏药对盐炙前后HPLC指纹图谱及多指标成分含量变化[J]. 中成药,2023,45(3):820-828. DOI:10.3969/j.issn.1001-1528.2023.03.022.
[22] 陆韫青,朱悦,郑嘉妮,等. 枸杞子-菊花配伍源流考证及特征分析[J]. 中草药,2022,53(6):1891-1902. DOI:10.7501/j.issn.0253-2670.2022.06.033.
[23] 曹馨慈,徐金娣,孔铭,等. 蝉蜕HPLC定量分析方法的建立和质量评价研究[J]. 中草药,2020,51(7):1909-1913. DOI:10.7501/j.issn.0253-2670.2020.07.028.
[24] 董玉洁,蒋沅岐,刘毅,等. 决明子的化学成分、药理作用及质量标志物预测分析[J]. 中草药,2021,52(9):2719-2732. DOI:10.7501/j.issn.0253-2670.2021.09.014.
[25] 钟育晟,程湧,赵明威,等. 新型冠状病毒感染相关急性黄斑神经视网膜病变的临床特征[J]. 中华眼底病杂志,2023,39(3):218-222. DOI:10.3760/cma.j.cn511434-20230204- 00043.
[26] 吴夕瑾,刘武. 继发于视网膜静脉阻塞的全层黄斑裂孔的研究进展[J]. 中华眼底病杂志,2023,39(9):783-786. DOI:10.3760/cma.j.cn511434-20220325-00171.
[27] 王文丽,李娟,赵旭. 生物有机肥对黄芪品质和根际土壤细菌群落的影响[J]. 中国土壤与肥料,2022(11):83-92. DOI:10.11838/sfsc.1673-6257.21571.
[28] 周琳,刘伟,韩硕,等. 舒洛地特联合羟苯磺酸钙治疗高血压合并2型糖尿病肾病患者的效果及对碳水化合物反应元件结合蛋白和分泌型卷曲相关蛋白5水平的影响[J]. 中华高血压杂志,2022,30(1):73-77. DOI:10.16439/j.issn. 1673-7245.2022.01.014.
[29] 闫丽,于晓明,张秀萍. 化瘀复明汤配合视网膜激光光凝治疗糖尿病视网膜病变疗效及对视野缺损和血脂、IL-6的影响[J]. 现代中西医结合杂志,2020,29(3):282-284,317. DOI:10.3969/j.issn.1008-8849.2020.03.013.

化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变患者的疗效观察

Curative effect of Huayu Fuming Decoction combined with calcium oxybenzenesulfonate capsules for patients with early diabetic retinopathy

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

[1]	田燕袁权王虎霞惠金子段绍雪. ABUS联合血清VEGF、CEA对乳腺癌的诊断价值 [J]. 国际医药卫生导报, 2024, 30(5): 740-743.
[2]	蒋骞陈毅飞陈雅秋朱志丹张嘉杰孙晓婧. 复方骨肽注射液对髁突骨折后大鼠颌骨发育的影响 [J]. 国际医药卫生导报, 2023, 29(17): 2446-2451.
[3]	辛秀. 那曲肝素钙联合阿司匹林治疗复发性流产的效果及对患者血清TSP-1、sflt-1水平影响[J]. 国际医药卫生导报, 2022, 28(9): 1288-1292.
[4]	张静. 黄芪甲苷对大鼠肠道缺血再灌注损伤的保护作用[J]. 国际医药卫生导报, 2022, 28(17): 2396-2399.
[5]	郭涛, 孟靓靓, 陈晓云, 陈燕, 张承芳. 不同胎龄新生儿和早产儿视网膜病变患儿血管内皮生长因子水平变化分析[J]. 国际医药卫生导报, 2021, 27(6): 840-843.